MAESTOSO: MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits

Sponsor

Moleac Pte Ltd. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05289947

Collaborator

(none)

300

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks.

Condition or Disease	Intervention/Treatment	Phase
Stroke Stroke, Ischemic Strokes Thrombotic Stroke Sequelae Stroke, Cardiovascular Stroke, Embolic Stroke, Cryptogenic	Other: Placebo Drug: MLC1501	Phase 2

Detailed Description

A total of 300 patients will be included with approximately 100 patients randomized to each treatment arm. Randomization will be performed centrally and stratified according to the following factors at the time of randomization: country, National Institute of Health Stroke Scale (NIHSS) (8 to 12, 13 to 18) and received either intravenous or endovascular thrombolysis/thrombectomy (no, yes).

Efficacy clinical assessments will include Fugl-Meyer motor Assessment (FMA), modified Rankin Scale (mRS), Patient Reported outcome Measurement Information System - Global Health (PROMIS-10) and NIHSS.

Each patient will undergo standard safety assessments including physical exam and laboratory parameters, and be observed for adverse events for the duration of the study. Electrocardiogram (ECG), hematology, clinical chemistry, coagulation, and urinalysis will be performed at specified intervals.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

300 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of MLC1501 in Patients With Stroke

Anticipated Study Start Date :

Jun 30, 2022

Anticipated Primary Completion Date :

May 30, 2024

Anticipated Study Completion Date :

May 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Placebo 500-mg placebo capsule, 4 capsules twice a day for 24 weeks	Other: Placebo Caramel, chocolate brown, flavor (E_1982648), dextrin
Active Comparator: MLC1501 Low-dose MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks	Drug: MLC1501 Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala
Active Comparator: MLC1501 High-dose MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks	Drug: MLC1501 Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala

Arm

Intervention/Treatment

Placebo Comparator: Placebo

500-mg placebo capsule, 4 capsules twice a day for 24 weeks

Other: Placebo

Caramel, chocolate brown, flavor (E_1982648), dextrin

Active Comparator: MLC1501 Low-dose

MLC1501 low-dose 500-mg capsule, 4 capsules twice a day for 24 weeks

Drug: MLC1501

Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala

Active Comparator: MLC1501 High-dose

MLC1501 high-dose 500-mg capsule, 4 capsules twice a day for 24 weeks

Drug: MLC1501

Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala

Outcome Measures

Primary Outcome Measures

Fugl-Meyer motor Assessment (FMA) [24 weeks]
The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia

Secondary Outcome Measures

Adverse events [up to 24 weeks]
Listing and calculating the number and percentage of subjects experiencing non-serious and serious adverse events for each dose cohort
Fugl-Meyer motor Assessment (FMA) [12 and 24 weeks]
modified Rankin Scale (mRS) [4, 12 and 24 weeks]
The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 (no symptoms at all) to 5 (severe disability). A separate category of 6 is usually added for patients who expire.
Patient Reported Outcome Measurement Information System - Global Health (PROMIS-10) [4, 12 and 24 weeks]
The PROMIS Global-10 is a 10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score. These scores are then standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient.
National Institute of Health Stroke Scale (NIHSS) [12 and 24 weeks]
The maximum possible score is 42 (severe), with the minimum score being a 0 (no symptoms)

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female.
≥18 years old or legal age as per country requirement
Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 10 days (inclusive) prior to inclusion.
NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 3 on the NIHSS motor items 5A or 5B and/or 6A or 6B.
A candidate for active rehabilitation in the opinion of the treating physician.
Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed.

Exclusion Criteria:

Pre-stroke modified Rankin score of >1.
Contraindication to any of the study procedures.
Patients who became medically unstable within 24 hours after intravenous or endovascular thrombolysis or thrombectomy.
Intake of any herbal or traditional medicine within the past 30 days.
Participation in another investigational drug or device trial within the past 30 days.
Intake of warfarin in the past one week or expected to be on warfarin while in the study.
Women who are pregnant or wish to continue breastfeeding while in the study. Women of child-bearing potential may be included if they agree to strict abstinence or use of effective contraception, except systemically acting hormonal contraceptives. Hormone replacement therapy in menopausal/post-menopausal or surgically sterilized women is also not allowed while in the study.
Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae/Leguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae/Umbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark).
Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability.
Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis.
Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his/her participation in this study, may hamper his/her ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Moleac Pte Ltd.

Investigators

Principal Investigator: Christopher Chen, BMBCh, MRCP, FAMS, FRCPE, Departments of Pharmacology and Psychological Medicine, National University of Singapore